We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Oyster Point Pharma Inc (OYST) USD0.001

Sell:$7.00 Buy:$7.01 Change: $0.95 (11.93%)
Market closed |  Prices as at close on 12 August 2022 | Switch to live prices |
Change: $0.95 (11.93%)
Market closed |  Prices as at close on 12 August 2022 | Switch to live prices |
Change: $0.95 (11.93%)
Market closed |  Prices as at close on 12 August 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Oyster Point Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of pharmaceutical therapies to treat ophthalmic diseases. The Company's lead product candidate is TYRVAYA Nasal Spray, a nicotinic acetylcholine receptor (nAChR) agonist for the treatment of the signs and symptoms of dry eye disease. TYRVAYA Nasal Spray’s is a mechanism of action, which is designed to re-establish tear film homeostasis by stimulating the trigeminal nerve, activating the trigeminal parasympathetic pathway (TPP) and stimulating the glands and cells responsible for natural tear film production. It is sprayed into the anterior portion of the nasal cavity and stimulates nAChRs located on the chemosensory endings of the trigeminal nerve resulting in cholinergic neurotransmission.

Contact details

202 Carnegie Ctr Ste 109
United States
+1 (609) 3829032

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$204.82 million
Shares in issue:
26.67 million
United States
US dollar

Key personnel

  • Jeffrey Nau
    President, Chief Executive Officer, Director
  • Daniel Lochner
    Chief Financial Officer, Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.